|33.72||-0.7400||-2.15%||Vol 744.52K||1Y Perf -61.85%|
|Jun 27th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||75.90||Analyst Rating||Strong Buy 1.22|
|Potential %||125.09||Finscreener Ranking||★★★+ 51.82|
|Insiders Trans % 3/6/12 mo.||-/-93/-94||Value Ranking||★★+ 48.55|
|Insiders Value % 3/6/12 mo.||-/-99/-100||Growth Ranking||★★★ 51.50|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-99/-100||Income Ranking||— -|
|Price Range Ratio 52W %||10.76||Earnings Rating||Sell|
|Market Cap||3.57B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|5 Years||1 968.71%|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Q04 2021||0.04||-0.61||-1 625.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2022|
|Estimated EPS Next Report||-0.45|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.08M|
|Avg. Monthly Volume||888.61K|
|Avg. Quarterly Volume||840.54K|
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock closed at 33.72 per share at the end of the most recent trading day (a -2.15% change compared to the prior day closing price) with a volume of 744.52K shares and market capitalization of 3.57B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Arrowhead Pharmaceuticals Inc. CEO is Christopher Anzalone.
The one-year performance of Arrowhead Pharmaceuticals Inc. stock is -61.85%, while year-to-date (YTD) performance is -49.14%. ARWR stock has a five-year performance of 1968.71%. Its 52-week range is between 26.81 and 91, which gives ARWR stock a 52-week price range ratio of 10.76%
Arrowhead Pharmaceuticals Inc. currently has a PE ratio of -26.70, a price-to-book (PB) ratio of 6.81, a price-to-sale (PS) ratio of 11.69, a price to cashflow ratio of 21.20, a PEG ratio of 2.32, a ROA of -15.77%, a ROC of -23.61% and a ROE of -25.61%. The company’s profit margin is -41.18%, its EBITDA margin is -41.30%, and its revenue ttm is $263.42 Million , which makes it $2.49 revenue per share.
Of the last four earnings reports from Arrowhead Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Arrowhead Pharmaceuticals Inc.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Arrowhead Pharmaceuticals Inc. is Strong Buy (1.22), with a target price of $75.9, which is +125.09% compared to the current price. The earnings rating for Arrowhead Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arrowhead Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arrowhead Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.57, ATR14 : 2.38, CCI20 : 68.71, Chaikin Money Flow : 0.07, MACD : -1.13, Money Flow Index : 65.59, ROC : -1.23, RSI : 53.97, STOCH (14,3) : 85.76, STOCH RSI : 1.00, UO : 61.17, Williams %R : -14.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arrowhead Pharmaceuticals Inc. in the last 12-months were: Christopher Anzalone (Sold 0 shares of value $-821 027 ), Christopher Anzalone (Sold 211 388 shares of value $11 873 844 ), Douglas B. Given (Buy at a value of $43 472), Douglas B. Given (Sold 5 000 shares of value $326 200 ), James Hamilton (Sold 25 625 shares of value $1 654 591 ), Kenneth Myszkowski (Sold 40 000 shares of value $2 467 941 ), Marianne De Backer (Sold 4 500 shares of value $291 177 ), Martin Javier San (Sold 19 500 shares of value $1 351 589 ), Mauro Ferrari (Sold 3 400 shares of value $227 188 ), Michael S. Perry (Sold 4 500 shares of value $291 192 ), William D. Waddill (Sold 4 500 shares of value $291 244 )
Sat, 11 Jun 2022 09:05 GMT Robert W. Baird Upgrades Arrowhead Pharmaceuticals (ARWR) to Buy- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.